XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Public ClinicalTrials.gov record NCT06959641. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer
Study identification
- NCT ID
- NCT06959641
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Northwestern University
- Other
- Enrollment
- 33 participants
Conditions and interventions
Conditions
- Locally Advanced Differentiated Thyroid Gland Carcinoma
- Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma
- Locally Advanced Thyroid Gland Follicular Carcinoma
- Locally Advanced Thyroid Gland Oncocytic Carcinoma
- Locally Advanced Thyroid Gland Papillary Carcinoma
- Metastatic Differentiated Thyroid Gland Carcinoma
- Metastatic Poorly Differentiated Thyroid Gland Carcinoma
- Metastatic Thyroid Gland Follicular Carcinoma
- Metastatic Thyroid Gland Oncocytic Carcinoma
- Metastatic Thyroid Gland Papillary Carcinoma
- Refractory Differentiated Thyroid Gland Carcinoma
- Refractory Poorly Differentiated Thyroid Gland Carcinoma
- Refractory Thyroid Gland Follicular Carcinoma
- Refractory Thyroid Gland Oncocytic Carcinoma
- Refractory Thyroid Gland Papillary Carcinoma
- Stage III Differentiated Thyroid Gland Carcinoma AJCC v8
- Stage III Thyroid Gland Follicular Carcinoma AJCC v8
- Stage III Thyroid Gland Papillary Carcinoma AJCC v8
- Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8
- Stage IV Thyroid Gland Follicular Carcinoma AJCC v8
- Stage IV Thyroid Gland Papillary Carcinoma AJCC v8
Interventions
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Magnetic Resonance Imaging Procedure
- Survey Administration Other
- X-Ray Imaging Procedure
- Zanzalintinib Drug
Procedure · Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 5, 2025
- Primary completion
- Sep 10, 2028
- Completion
- Sep 10, 2030
- Last update posted
- Jun 10, 2025
2025 – 2030
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwestern University | Chicago | Illinois | 60611 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06959641, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06959641 live on ClinicalTrials.gov.